HDAX Therapeutics

HDAX Therapeutics is dedicated to developing transformative therapies targeting HDAC6 for neurological and cardiometabolic diseases. Their proprietary 2-site binding technology enhances drug efficacy, safety, and pharmacokinetics, aiming to address significant unmet medical needs. With a foundation in translational science and a strong entrepreneurial spirit, HDAX is positioned to revolutionize treatment paradigms and improve patient outcomes across multiple indications.